Original Article

Desloratadine: An Insight On Acute Inflammation

Nisha[1], Omveer Singh[2], Sandeep Rathor[2*], Sadia Parveen[3], Soma Ghosh[4], Shailesh Sharma[5], Hina Sharma[1], Nitish Gaur[1]

[1]Shivdan Singh Institute of Technology and Management Aligarh.
[2]MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be university), Mullana-133207, Ambala, India.
[3]Nims Institute of Pharmacy, Nims University Rajasthan Jaipur
[4]Jharkhand Rai University, Kamre, Ratu Rd., Ranchi-835222
[5]Shayam University, Lalsot Bypass, Dausa, Rajasthan
Corresponding Author: omveerpharmd123@gmail.com
DOI: 10.47750/pnr.2023.14.02.73

Abstract

In allergic inflammatory diseases, histamine plays a significant role. Histamine H1 receptor antagonists, also referred to as antihistamines, have been used to treat allergies for a long time. They are believed to work by inhibiting the inflammatory responses brought on by the release of histamine. Mast cells, basophils, lymphocytes, and other reservoirs contain granules that release histamine, a short peptide with inherent vasoactive properties. Histamine interacts with histamine receptors to control a number of cellular processes involved in the control of allergic inflammation and the immune system.Here, we examine mounting evidence that histamine does, in fact, play a part in inflammation and the regulation of immune function in these disorders. In particular, the identification of the fourth histamine receptor (H4) and its widespread expression on immunological and inflammatory cells.

Keywords: Histamine, Histamine receptors, Inflammation, Antihistamine Drugs.

Introduction: Inflammation is an immunological response, to the introduction of foreign substances into the body or the failure of tissue healing is inflammation. By enlisting immune cells, which can attach to or remove foreign substances or damaged tissue, it defends our bodies from such detrimental external or internal stimuli [2, 5, 6]. Its goal is to find and get rid of the harmful substance and get rid of the damaged tissue pieces so that the body may start healing. The reaction entails adjustments in blood flow, an increase in blood vessel permeability, and the movement of fluid, proteins, and white blood cells (leucocytes) from the circulation to the site of tissue damage and Clinical care of different illnesses, including eye and urinary tract infections, brain tumours, and liver cirrhosis. [18, 24]. Acute inflammation is a limited-duration inflammatory response, but chronic inflammation is used to describe a response that lasts longer. It has been demonstrated that histamine binds to four different types of G-protein-coupled histamine receptors that are variable expressed in various cell types, acting as a pathophysiological regulator of cellular functions. [14,18]. Widely present throughout the body The rate-limiting enzyme histidine decarboxylase synthesizes the endogenous short-acting biogenic amine histamine [2-(4-imidazolyl)-ethylamine] from the basic amino acid histidine.,. Its capacity to imitate anaphylaxis was one of the first documented roles, and it has since been shown to play a significant part in inflammatory processes. Histamine is a physiologically active chemical that is present in a wide range of living things [22]. The main characteristics of toe and fingernail diseases include discoloration and pitting. [23].

Histamine: An autacoid known as histamine has been identified as a key mediator in the development of allergic reactions and illnesses [2,7]. Tissue mast cells and basophils produce and store it in cytoplasmic granules.

Histamine is released in huge amounts by non-cytotoxic processes during the early stage of IgE-mediated responses, which is the most significant mechanism for its release in response to immunological stimuli [4, 5, 10].

Source of Histamine:

Histamine's production was discovered in 1907, and Barger and Dale described it as a chemical ("beta-1") that could contract the ileum of guinea pork in 1910. The swelling and itching that result from contact with stinging nettle leaves are partially caused by the histamine found in the hair-like structures on those leaves.; stinging nettles are plants that manufacture histamine [3]. Histamine is another unpleasant component found in the venom of numerous wasp and bee species. In humans, histamine may be found in almost all body tissues. It is largely kept in the granules of tissue mast cells. Histamine-containing granules are also seen in the blood cells known as basophils. [12,17].

Histamine Receptors: One of the four distinct histamine receptors, known as H1, H2, H3, or H4, in target cells is activated to mediate histamine activity [11].



Role of Histamine Receptors in Allergic Inflammation

Histamine receptors (H1R-H4R) are classified according to how they work, how they are distributed, and how much they bind to histamine. The pro- and anti-inflammatory actions of histamine depend on the cell types activated by it as well as the histamine receptor subtype. While the H2-receptor affects gastric acid secretion, airway mucus formation, and vascular permeability, the H1-receptor causes cellular migration, nociception, vasodilatation, and bronchoconstriction. The H3-receptor is crucial in the development of neuro-inflammatory disorders. It has also been demonstrated that the H4-receptor plays a role in inflammation and allergies. By releasing a number of inflammatory mediators, H4R-mediated mast cell activation can control an intense inflammatory cascade. These mediators may also encourage the migration of other inflammatory cells into the inflammatory region. Similarly, H1R activation controls allergic reactions by promoting the movement of Th2 cells toward the allergen during lung inflammation.

The Histamine H1 Receptor

Histamine research prior to the 1970s concentrated on the function of histamine in allergic disorders. The H1R is widely expressed and contributes to allergies and inflammation. H1R is expressed in a variety of organs and cells, including lymphocytes, respiratory epithelium, endothelial cells, hepatic cells, vascular smooth muscle cells, and

neurons.The initial generation of H1 receptor antagonists, however, which were developed to treat allergies, manifested different adverse effects, such as drowsiness. Due to structural alterations, the medications' ability to cross the blood-brain barrier was blocked, preventing this specific physiological action of the ligands.

The Histamine H2 Receptor

Schild and Ash proposed the existence of two separate subtypes of histamine receptors in 1966 as a result of the observation that the traditional "antihistamines" (i.e., H1 receptor inverse agonists) could not counteract all histamine-induced effects (such as those at the heart and stomach). Many different types of cells and tissues, including B cells, T cells, dendritic cells, gastricparietal cells, smooth muscle cells, the brain, and cardiac tissue, have high levels of the Gas-coupled H2R expression. The receptor's activation can lead to the generation of vascular permeability, stomach acid secretion, and mucus in the airways. Histidine decarboxylase knockout mice (HDC/), whose H2R function is well characterized, show that the absence of histamine can cause a tissue-specific up regulation of H2R expression. The H2R is also crucially responsible for the relaxation of the uterus, blood vessel smooth muscle cells, and airways. Additionally, the H2R is involved in immune system activation, including Th1 cytokine production, basophil degranulation decrease, T-cell proliferation, and antibody formation.

The Histamine H3 Receptor

In the 1980s, histamine's physiological significance as a neurotransmitter and another physiological function became clear. It is crucial for the homeostatic control of inflammation, cognition, sleep-wake cycles, and energy levels. The behaviour and locomotion of H3R-deficient mice are altered, and they manifest the metabolic syndrome, which is characterised by obesity, hyperplasia, and elevated levels of leptin and insulin. Additionally, a number of studies indicate that H3R deletion can increase the expression of IFN-inducible protein 10, MIP 2, and CXCR3 in T cells as well as the severity of neuro-inflammatory illnesses. Additionally, these researchers demonstrated that H3R can play a role in blood-brain barrier function.

The Histamine H4 Receptor

Following the cloning of the H3 receptor gene, numerous groups found the equivalent H4 receptor sequence in the human genome databases. In fact, the H4 receptor and the H3 receptor share a high degree of sequence similarity (54% in the trans membrane domains and 31% in the protein). A range of immune cells as well as other cells such the spleen, intestinal epithelia, lung, synovial tissue, central nervous system, sensory neurons, and cancer cells express the histamine H4R, which is connected to G/io proteins.

Release of Histamine: The mast cell and the white blood cells known as basophils and eosinophils are where the majority of the body's histamine is produced in granule form. In places that could be harmed, the nose, mouth, foot, internal body surfaces, and blood vessels all have a lot of mast cells.. In the brain, where it serves as a neurotransmitter, non-mast cell histamine can be found in a number of tissues [22] the main pathophysiologic mechanism for basophil and mast cell histamine release is immunologyWhen exposed to the proper antigen, these cells degranulation if IgE antibodies are sensitised by their membranes. IgE antibodies linked to mast cells trigger histamine release when allergens bind to them. The risk that allergens will find enough free IgE to cause a mast cell to release histamine can be decreased by reducing the overproduction of IgE [12, 18].



Action of Histamine on Inflammation: Numerous inflammatory and hypersensitive side effects, including as Histamine causes smooth muscle contraction, edema, vasodilation, and an increase in vascular permeability. Increased vascular permeability results from fluid leaking from capillaries into the tissues, which causes the classic symptoms of an allergic reaction, such as a runny nose and watery eyes. Although histamine H1 antagonists have little impact on acute inflammation, histamine is believed to be a crucial regulator of the acute inflammatory response. [2,8]. Histamine is a critical component of numerous allergic and inflammatory processes, including both acute and delayed hypersensitivity reactions. The source of the histamine in these circumstances is tissue mast cells. The severity of these issues is influenced by the method of exposure (local versus systemic), the place of exposure (for instance, inhaled versus cutaneous), the concentration of allergen, and the level of prior sensitization to the allergen. Clinical symptoms of histamine release range from localized wheals and flare-ups to potentially fatal anaphylactic reactions. Numerous allergic reaction symptoms are caused by histamine's ability to affect blood vessels, which results in vascular permeability, vasodilation, and increased blood flow. [2,8,9].

Antihistamine: Antihistamines are used to treat allergic diseases. They are helpful for relieving the itching brought on by histamine release.

Promethazine and other 'first generation' antihistamines from the past induced sedation. With more recent "second generation" and "third generation" antihistamines, including loratadine and desloratadine, this is less of an issue.

In the table, you'll find a list of the oral antihistamines that are available in Australia to treat allergic disorders. Desloratadine and fexofenadine are approved for usage in infants six months of age and beyond, whilst loratadine and cetirizine can be started on at 12 months of age. Due to their calming or antinausea effects, several antihistamines are used

TABLE-1 Oral antihistamines used to treat allergy conditions are readily available in Australia.

Sedating H1 antihistamines	Cyproheptadine Dexchlorpheniramine Pheniramine Promethazine Trimeprazine
Less sedating H1 antihistamines	Cetirizin Desloratadine Fexofenadine Loratadine

Pharmacology: Antihistamines interact with histamine receptors on cell surfaces. Histamine receptors come in four different varieties in the body (H1–H4), with H1 and H2 having the highest levels of expression. Airway and vascular smooth muscle cells, endothelium and epithelial cells, eosinophils, and neutrophils are just a few of the cells that have H1 histamine receptors[2,4,5].The receptors bind histamine, but they also have a built-in signaling mechanism that works even when histamine isn't interacting with the cell surface. A balance exists between the receptor's active and inactive states. The active form of the receptor is stabilised by the presence of histamine, whereas the inactive form of the receptor is stabilised by the presence of antihistamines. Inverse agonists are consequently produced by the H1 antihistamine medications. Cetirizine, desloratadine, and fexofenadine do not undergo significant metabolic processing, whereas loratadine is metabolised in the liver [16,9].

Newer Antihistamine: Less sedative H1 antihistamines are more recent versions. There aren't many long-term head-to-head studies, despite the fact that all the newer medications seem to be similarly effective in small studies. Therefore, the patient can select the specific medication that they believe works best or the formulation (tablet size) that works best for them. The decision for paediatric suspensions may be influenced by a chosen flavor [9, 7].

Second-Generation Antihistamine Drugs Used in the treatment of Anti-Inflammatory

Different second-generation antihistamines have different pharmacologies, which may affect how well they suppress the proinflammatory mediators linked to an allergic reaction as it develops (Table 1). Antihistamines can reduce inflammation in a variety of ways, some of which appear to depend on first interacting with the histamine receptor. If these variations in anti-inflammatory pharmacology have clinically significant effects, further research is required to ascertain this [10, 17].

TABLE-2 Compounds are use as Duration of action in h and Protein binding, %.

Compounds	Onset of action, h	Duration of action, h	Protein binding, %
Cetirizine	0.7	24	93
Desloratidine	3	24	95
Fexofenadine	1-2	24	60-70
Levocetirizine	0.5	>24	96

The active metabolite of loratadine, desloratadine, is a second-generation oral antihistamine with safety and tolerability features similar to placebo and efficacy shown in randomised, controlled clinical trials. [12, 18] Desloratadine is prescribed for the treatment of urticarial and intermittent and persistent AR in adults and children older than one year old in the European Union. Desloratadine has been given the go-ahead in the US to treat perpetual AR, chronic idiopathic urticarial (CIU), in adults and children older than 6 months, as well as seasonal AR in those people and children older than 2 years. Desloratadine suppresses a number of inflammatory mediators in addition to having considerable H1-receptor antagonist effects, as do antihistamines like levocetirizine (the active enantiomer of cetirizine) and others, according to in vitro studies, animal model studies, and in vivo tests. New research increasing the antihistaminic, anti-inflammatory, and anti-allergic properties of desloratadine will be presented in the current review. [14, 13]

Desloratadine's effects on allergies, inflammation, and histamine

Desloratadine interacts with the H1-receptor more effectively than cetirizine, ebastine, fexofenadine, and loratadine, respectively (Table 1); the observed alteration in histamine-induced intracellular calcium served as the study's effector end aim. Only 37% of the desloratadine remains bound at 6 hours, indicating pseudo-irreversibility and supporting a longer duration of effect. Desloratadine slowly separates from the receptor after becoming linked to it. [11] A second-generation antihistamine known as desloratadine demonstrates inverse agonism, which reduces downstream messaging by spontaneously activated receptors. Compared to equal amounts of cetirizine, fexofenadine, loratadine, or pyrilamine, desloratadine efficiently reduced downstream signaling of a constitutively active human H1-receptor linked to NF-B production. Desloratadine was also more effective than its counterparts in preventing the development of NF-B after histamine activated the receptor. [19].

Pharmacodynamics: A second-generation H1-receptor antagonist with a lengthy half-life and peripheral H1-antagonist effect is desloratadine. Many of the symptoms of allergic reactions, such as tissue swelling, are brought on by the chemical histamine. Histamine is released from cells that store it (mast cells) and binds to other cells that contain histamine receptors. Histamine binds to the receptors on the cell, "activating" it and causing it to release more chemicals that result in the symptoms we associate with allergies. Desloratadine stops histamine from activating cells by blocking the H1 receptor, one kind of histamine receptor. Desloratadine does not enter the brain from the blood like the majority of other antihistamines and does not make you sleepy [12, 16, 19]

Mechanism of Action: Desloratadine competes with free histamine for binding at H1-receptors in the gastrointestinal tract, uterus, major blood arteries, and bronchial smooth muscle, just like other H1-blockers do [18, 19]. This prevents endogenous histamine from acting, which in turn temporarily relieves histamine-related unpleasant symptoms (such as nasal congestion and watery eyes) [21, 22] Loratadine and Desloratadine Effects on Inflammatory Mediators



Anti-Inflammatory Effects of Loratadine & desloratadine

We first investigated the levels of mRNA expression of pro-inflammatory genes as well as the activation of transcription factor AP-1 under inflammation-triggered settings to ascertain whether or not Loratadine had anti-inflammatory effects on the transcriptional level.



Anti-Inflammatory activities of an antihistamine drug loratadine

We further investigated Loratadine anti-inflammatory effect in TAK1-overexpressing cells to discover whether TAK1 is the drug's principal target. Toxic levels of inflammation comparable to those seen in cells treated with LPS can be produced by overexpressing TAK1 and its downstream components [18, 21]. We chose to examine the expression of inflammatory cytokines after TAK1 overexpression first**.**

Conclusion: Recent advancements in the study of the histamine pathway highlight the significance of histamine in allergic inflammation due to its interactions with the H1R and H4R. Although H1R-targeting medications are being investigated for the treatment of a variety of allergy diseases involving mast cells, they are not always clinically effective. For a variety of allergy and inflammatory illnesses, several H4R antagonists have advanced to the final stages of clinical testing. However, the desloratadine concentrations used in these trials are frequently higher than what is clinically achieved at the dosage that is now advised. Desloratadine dose escalation may result in a more robust anti-inflammatory effect, according to dose-dependent suppression of the inflammatory response observed in vitro. Information is mounting showing desloratadine may influence elements of inflammation via mechanisms other than inhibition of H1-histamine receptors. Investigation into potential mechanisms is still needed.

Reference:

1. Akdis CA, Simons FER. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006;533:69–76 [PubMed] [Google Scholar]

2. Akdis CA, Jutel M, Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy. 2008;94:67–82 [PubMed] [Google Scholar]

3. Schneider E, Rolli-Derkinderen M, Arock M, Dy M. Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol. 2002;23:255–263 [PubMed] [Google Scholar]

4. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy. 2001;56:21–27 [PubMed] [Google Scholar]

5. Zuberbier T, Asero R, Bindslev-Jensen C. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64:1418–1426 [PubMed] [Google Scholar]

6. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov. 2008;7:41–53 [PubMed] [Google Scholar]

7. Das AK, Yoshimura S, Mishima R, Fujimoto K, Mizuguchi H, et al. Stimulation of histamine H1 receptor up-regulates histamine H1 receptor itself through activation of receptor gene transcription. J Pharmacol Sci. 2007;103:374–382 [PubMed] [Google Scholar]

8. Simons FER. Advances in H1-antihistamines. N Engl J Med. 2004;351:2203–2217 [PubMed] [Google Scholar]

9. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160 [PubMed] [Google Scholar]

10. Zuberbier T, Asero R, Bindslev-Jensen C. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64:1427–1443 [PubMed] [Google Scholar]

11. del Cuvillo A, Mullol J, Bartra J, Dávila I, Jáuregui I, et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16(Suppl 1):3–12 [PubMed] [Google Scholar]

12. Scadding G. Predicting and establishing the clinical efficacy of a histamine H1- receptor antagonist: desloratadine, the model paradigm. Clin Drug Invest. 2005;25:153–164 [PubMed] [Google Scholar]

13. Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med. 2002;113(Suppl 9A):38S–46S [PubMed] [Google Scholar]

14. Lippert U, Möller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol. 2000;9:118–124 [PubMed] [Google Scholar]

15. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32:489–498 [PubMed] [Google Scholar]

16. Bousquet J, Bachert C, Canonica GW, Mullol J, Van Cauwenberge P, et al., ACCEPT-1 Study Group Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study. Allergy. 2009;64:1516–1523 [PubMed] [Google Scholar]

17. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123:672–679 [PubMed] [Google Scholar]

18. Zuberbier T, Canonica GW. Desloratadine significantly decreases total symptoms scores in subjects with persistent allergic rhinitis: ACCEPT-2 study in collaboration with GA2LEN. Ann Allergy Asthma Immunol. 2009;102:A119 [Google Scholar]

19. Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007;62:359–366 [PubMed] [Google Scholar]

20. Ortonne J-P, Grob J-J, Auquier P, Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol. 2007;8:37–42 [PubMed] [Google Scholar]

21."Histamine and Antihistamines." Anaesthesia & Intensive Care Medicine, Elsevier, 24 June 2011. Available here

22. "Antihistamine." Wikipedia, Wikimedia Foundation, 24 Sept. 2018. Available here.

23. Mahbubur Rahman, Omveer Singh et al., A Review on Psoriasis 2022: 20 , 16, 5786-5793.
24. Rathor, Sandeep et al., A Comprehensive Review on Microbubble Concept, Development and Its Application in Therapeutic Drug Delivery and Clinical Management of Disease, Current Pharmaceutical Biotechnology, Volume 22, Number 11, 2021, pp. 1424-1443(20).

AUTHOR PROFILE

Dr. OMVEER SINGH
B PHARM, PHARM D (DOCTOR OF PHARMACY) (P.B.)
Department of Pharmacy Practice, **Maharishi Markandeshwar (Deemed to be University),Ambala - Yamunanagar Highway, Mullana - Ambala, 133-207 (Haryana)**. He Has Been Completed B Pharm from Nims University Jaipur Rajasthan and Pharm D (Pb) From Nims University, Jaipur, Rajasthan. And, He Had More Than 4 Years of Teaching Experience as an Assistant Professor in Department of Pharmacy Practice. He Had 6 Months of Experience As A Director In Lifecare Pvt. Ltd. Company. He Had Done Pharm D. Project on The Topic of ―The Assessment of Stress & Obesity As Risk Factors For Cardiovascular Diseases In The Cardiology Department of A Tertiary Care Teaching Hospital.‖ ; A Prospective Study**.** He Is Actively Involved In Research. He has published 6 patents in Indian patent window. He has published more than 23 high quality papers in international and national journals of repute; with high citation score. He Has Attended More Than 250 Conferences at National and International Level. He is author of 4 books, ―PHARMACY PRACTICE‖, ―PHARMACOTHERAPEUTICS, PHARMACEUTICAL CHEMISTRY‖ and ―PHYSICAL PHARMACEUTICS‖ in the Different-Different Publications as per the syllabus prescribed by the Pharmacy Council of India.